Update shared on16 Sep 2025
Fair value Increased 2k%The substantial increase in Biodesix’s consensus price target is accompanied by a modest improvement in forward earnings valuation and a slight rise in discount rate, indicating more favorable future expectations despite a marginally higher cost of capital, with fair value rising markedly to $35.00.
What's in the News
- Biodesix announced a 1-for-20 stock split.
- The company reaffirmed 2025 revenue guidance at $80 million to $85 million.
Valuation Changes
Summary of Valuation Changes for Biodesix
- The Consensus Analyst Price Target has significantly risen from $1.75 to $35.00.
- The Future P/E for Biodesix has fallen slightly from 46.30x to 44.39x.
- The Discount Rate for Biodesix has risen slightly from 7.44% to 7.68%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.